💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical products segment. Its geographical segments include within India and outside India. The Company has a presence across the pharmaceutical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, fully valued.
Granules India is scored on the pharma / healthcare framework. It keeps a healthy 11.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.33× reported profit. Free cash flow is worth about 0.1% of its market value.
Over the last 3 years revenue compounded at 6%/yr and profit at 5%/yr. Book value itself has compounded 22%/yr — the hallmark of a genuine compounder. Return on equity is a modest 10.9%. In the latest quarter profit fell 11% versus the prior quarter.
At 33× earnings, the stock sits at the 77th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price implies ~15%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 30.58 | — | — |
| P/B | 3.32 | 4.1 | better |
| EV/EBITDA | 15.52 | 19.33 | better |
| ROE | 10.87 | — | — |
| ROCE | 13.72 | 14.41 | worse |
| ROA | 8.04 | 1.64 | better |
| Quick Ratio | 1 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
6% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Operating margins have been stable around 15% — no major structural shift.
ROE at 12% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 7pp.
5% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.3× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 10% above earlier ones.
Profit fell 11% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (10% → 12%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 37.4% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction. Both FII and MF added last quarter — broad institutional confidence.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.